Healthcare / Diagnostics & ResearchParis
$15900.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$80M
P/E
16.8x
↓EV/EBITDA
11.0x
↓ROE
6.3%
↑Gross Margin
53.5%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.9%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $41.0M · net income $4.8M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $41.0M | $41.0M | $40.5M | $44.1M | $47.6M |
| Net Income | $4.8M | $4.8M | $7.2M | $7.6M | $11.5M |
| EBITDA | $6.5M | $6.5M | $8.9M | $9.1M | $12.9M |
| EPS | 948.15 | 948.15 | 1418.41 | 1514.43 | 2284.78 |
| Gross Margin | 53.5% | 53.5% | 43.1% | 45.9% | 49.6% |
| Operating Margin | 8.8% | 8.8% | 11.0% | 14.6% | 24.6% |
| Net Margin | 11.7% | 11.7% | 17.7% | 17.3% | 24.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 7.83 | 7.83 | — | — | — |
| Returns | |||||
| ROE | 6.3% | 6.3% | 10.0% | 11.8% | 20.2% |
| Valuation | |||||
| P/E | 16.78 | 16.78 | 13.82 | 16.51 | 9.72 |
| EV/EBITDA | 10.95 | 10.95 | 9.18 | 12.91 | 7.66 |
| P/B | 1.05 | 1.05 | 1.38 | 1.95 | 1.97 |
| Growth & Yield | |||||
| Revenue Growth | 1.3% | 1.3% | -8.2% | -7.5% | — |
| EPS Growth | -33.2% | -33.2% | -6.3% | -33.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
14.2%
EPS terminal req.
$1410.86
Spread vs growth
-47.3%
5Y implied EPS CAGR
12.5%
EPS terminal req.
$1707.14
Spread vs growth
-45.6%
10Y implied EPS CAGR
11.2%
EPS terminal req.
$2749.37
Spread vs growth
-44.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.8%
Start / end P/E
14.5x → 16.8x
EPS bridge
1418.41 → 948.15
Residual
-5.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.